406 related articles for article (PubMed ID: 32365759)
21. Relevance of multidrug resistance in the age of targeted therapy.
Türk D; Szakács G
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):246-52. PubMed ID: 19333870
[TBL] [Abstract][Full Text] [Related]
22. Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors.
Shao J; Markowitz JS; Bei D; An G
J Pharm Sci; 2014 Dec; 103(12):3810-3833. PubMed ID: 25308414
[TBL] [Abstract][Full Text] [Related]
23. Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR).
Lee CH
Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):43-52. PubMed ID: 14754411
[TBL] [Abstract][Full Text] [Related]
24. The Lysosomal Sequestration of Tyrosine Kinase Inhibitors and Drug Resistance.
Ruzickova E; Skoupa N; Dolezel P; Smith DA; Mlejnek P
Biomolecules; 2019 Oct; 9(11):. PubMed ID: 31683643
[TBL] [Abstract][Full Text] [Related]
25. Tumor stressors induce two mechanisms of intracellular P-glycoprotein-mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones.
Al-Akra L; Bae DH; Sahni S; Huang MLH; Park KC; Lane DJR; Jansson PJ; Richardson DR
J Biol Chem; 2018 Mar; 293(10):3562-3587. PubMed ID: 29305422
[TBL] [Abstract][Full Text] [Related]
26. Antitubercular Agent Delamanid and Metabolites as Substrates and Inhibitors of ABC and Solute Carrier Transporters.
Sasabe H; Shimokawa Y; Shibata M; Hashizume K; Hamasako Y; Ohzone Y; Kashiyama E; Umehara K
Antimicrob Agents Chemother; 2016 Jun; 60(6):3497-508. PubMed ID: 27021329
[TBL] [Abstract][Full Text] [Related]
27. Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism.
Joyce H; McCann A; Clynes M; Larkin A
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):795-809. PubMed ID: 25836015
[TBL] [Abstract][Full Text] [Related]
28. Marine Natural Products as Models to Circumvent Multidrug Resistance.
Long S; Sousa E; Kijjoa A; Pinto MM
Molecules; 2016 Jul; 21(7):. PubMed ID: 27399665
[TBL] [Abstract][Full Text] [Related]
29. ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy.
Dlugosz A; Janecka A
Curr Pharm Des; 2016; 22(30):4705-4716. PubMed ID: 26932159
[TBL] [Abstract][Full Text] [Related]
30. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies.
Li W; Zhang H; Assaraf YG; Zhao K; Xu X; Xie J; Yang DH; Chen ZS
Drug Resist Updat; 2016 Jul; 27():14-29. PubMed ID: 27449595
[TBL] [Abstract][Full Text] [Related]
31. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
32. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
33. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.
Cihalova D; Staud F; Ceckova M
Cancer Chemother Pharmacol; 2015 Jul; 76(1):105-16. PubMed ID: 25986678
[TBL] [Abstract][Full Text] [Related]
34. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
35. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
36. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
[TBL] [Abstract][Full Text] [Related]
37. Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors.
Neul C; Schaeffeler E; Sparreboom A; Laufer S; Schwab M; Nies AT
Trends Pharmacol Sci; 2016 Nov; 37(11):904-932. PubMed ID: 27659854
[TBL] [Abstract][Full Text] [Related]
38. Molecular Modeling Strategies of Cancer Multidrug Resistance.
Yalcin-Ozkat G
Drug Resist Updat; 2021 Dec; 59():100789. PubMed ID: 34973929
[TBL] [Abstract][Full Text] [Related]
39. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
[TBL] [Abstract][Full Text] [Related]
40. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
